Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

18 criteria for choosing GSK's Cervarix

This article was originally published in Scrip

Executive Summary

For those wondering how the department of health chose between GlaxoSmithKline's Cervarix and Sanofi Pasteur MSD's Gardasil for the UK's cervical cancer vaccine campaign (Scrip No 3373, p 1), health minister Dawn Primarolo has listed in a recent parliamentary answer the 18 criteria that were used. As well as the obvious clinical and cost reasons, the criteria include pallet configuration, the robustness of manufacturing contingency arrangements, the risk of wastage if subjected to temperatures above 8°C, and the closeness of delivery schedules to requirements.

You may also be interested in...



Vectura Reaps Value From Pan-JAK Inhibitor For Severe Asthma

The UK’s Vectura plc is gaining value from its back catalog of novel compounds through licensing its pan-JAK inhibitor, VR588, to a US start-up, the venture capital-backed Kinaset Therapeutics.

Pipeline Watch: Phase III Starts In RSV Prophlyaxis, Dry Eye Disease

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Jefferies' Survey Predicts M&A Rebound In 2021

An upturn in M&A activity across the whole healthcare sector is expected in 2021, with the COVID-19 pandemic and the associated development of a vaccine shining a light on the sector, says a recent survey by Jefferies. 

Topics

Related Companies

UsernamePublicRestriction

Register

OM006664

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel